Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

The site is the third of four new facilities in the U.S. that the pharmaceutical company plans to announce, Eli Lilly said.

French biotech company Abivax's shares rose by over 20% on Wednesday on market rumours that U.S. pharma giant Eli Lilly could ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Fintel reports that on December 15, 2025, B of A Securities maintained coverage of Eli Lilly and (NYSE:LLY) with a Buy ...

Eli Lilly said on Tuesday it will invest more than $6 billion in a new active drug ingredient manufacturing facility in ...

Eli Lilly and Company (NYSE: LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on ...

Eli Lilly 's (NYSE: LLY) share price has soared over the past five years (up 530%). In fact, it's hard to find a single ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.